<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179008</url>
  </required_header>
  <id_info>
    <org_study_id>33-003</org_study_id>
    <nct_id>NCT02179008</nct_id>
  </id_info>
  <brief_title>Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension</brief_title>
  <acronym>SEE-1</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of five concentrations of
      DE-117 ophthalmic solution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 90-day randomized, observer-masked, active-controlled, parallel-group,
      multi-center, study assessing the safety and efficacy of five concentrations of DE-117
      ophthalmic solution when compared to latanoprost (0.005% latanoprost) in subjects with
      primary open-angle glaucoma or ocular hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (mmHg)</measure>
    <time_frame>Day 91</time_frame>
    <description>Intraocular pressure (mmHg) measurements will be collected using Goldmann applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Day 1, Day 8, Day 15, Day 31, Day 61 and Day 91</time_frame>
    <description>Adverse events will be assessed at each visit to evaluate safety</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>DE-117 Low Dose ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop Low Dose DE-117 in each eye QD for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 Low/Middle Dose ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop DE-117 Low/Middle Dose ophthalmic solution in each eye QD for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 Middle Dose ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop Middle Dose DE-117 in each eye QD for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 Middle/High Dose ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop Middle/High Dose DE-117 in each eye QD for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 High Dose ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop High Dose DE-117 in each eye QD for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost ophthalmic solution 0.005%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop latanaprost in each eye QD for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 Low Dose ophthalmic solution</intervention_name>
    <description>Low Dose DE-117 ophthalmic solution</description>
    <arm_group_label>DE-117 Low Dose ophthalmic solution</arm_group_label>
    <other_name>DE-117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 Low/Middle Dose ophthalmic solution</intervention_name>
    <description>Low/Middle Dose DE-117</description>
    <arm_group_label>DE-117 Low/Middle Dose ophthalmic solution</arm_group_label>
    <other_name>DE-117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 Middle Dose ophthalmic solution</intervention_name>
    <description>Middle Dose DE-117</description>
    <arm_group_label>DE-117 Middle Dose ophthalmic solution</arm_group_label>
    <other_name>DE-117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 Middle/High Dose ophthalmic solution</intervention_name>
    <description>Middle/High Dose DE-117</description>
    <arm_group_label>DE-117 Middle/High Dose ophthalmic solution</arm_group_label>
    <other_name>DE-117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 High Dose ophthalmic solution</intervention_name>
    <description>High Dose DE-117</description>
    <arm_group_label>DE-117 High Dose ophthalmic solution</arm_group_label>
    <other_name>DE-117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost ophthalmic solution 0.005%</intervention_name>
    <description>0.005% latanoprost</description>
    <arm_group_label>latanoprost ophthalmic solution 0.005%</arm_group_label>
    <other_name>latanoprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes

          -  Qualifying intraocular pressure in at least one eye at Baseline

          -  Qualifying corrected ETDRS visual acuity in each eye

          -  Qualifying central cornea thickness in each eye

        Exclusion Criteria:

          -  Closed/barely open anterior chamber angle or a history of acute angle closure in
             either eye

          -  Diagnosis of primary open-angle glaucoma or ocular hypertension due to etiology known
             to be non-responsive to conventional drug therapy

          -  Evidence of advanced glaucoma, visual field defect or progressive visual field loss
             that that do not meet the study criteria

          -  History of ocular surgery specifically intended to lower IOP

          -  History of any ocular or systemic abnormality or condition that may put the subject at
             significant risk, may confound study results, or may interfere significantly with the
             subject's participation in the study

          -  Intended or current use of any ocular medications other than study medications during
             the study

          -  Use of contact lenses within one week prior to Baseline (Day 1) until end of treatment

          -  Known allergy or sensitivity to any components of the study medications

          -  Use of steroids (systemic) within 30 days prior to Visit 1 (Screening)

          -  Anticipate the need to initiate or modify an existing chronic therapy that could
             substantially affect IOP or the study outcomes during the study period

          -  Females who are pregnant, nursing or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Santen</keyword>
  <keyword>Eye</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

